Rebound. The company confirmed that it will receive a lump sum payment from Kyukou Seiyaku for a patch including a new sodium channel blocker (RQ-00350215). The company will grant Kyukou Seiyaku exclusive rights to develop, manufacture, and sell the compound worldwide, and will receive rights to milestones based on the development stages, sales royalties and sales milestones based on product revenue. This time, Kyukou Seiyaku achieved a development milestone, leading to the receipt of a 0.1 billion yen lump sum, to be recorded as business income in the fourth quarter of the fiscal year ending in December 24.
ラクオリア創薬---反発、久光製薬から一時金を受領
Rakuolia Pharmaceuticals---Received a one-time payment from Kyukou Pharmaceutical due to a dispute.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.